These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 12212795)
1. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. Windisch M; Hutter-Paier B; Rockenstein E; Hashimoto M; Mallory M; Masliah E J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795 [TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Bayer TA; Jäkälä P; Hartmann T; Havas L; McLean C; Culvenor JG; Li QX; Masters CL; Falkai P; Beyreuther K Neurosci Lett; 1999 May; 266(3):213-6. PubMed ID: 10465711 [TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Jellinger KA Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452 [TBL] [Abstract][Full Text] [Related]
4. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944 [TBL] [Abstract][Full Text] [Related]
5. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders? Windisch M; Hutter-Paier B; Schreiner E; Wronski R J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265 [TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Mattila PM; Rinne JO; Helenius H; Dickson DW; Röyttä M Acta Neuropathol; 2000 Sep; 100(3):285-90. PubMed ID: 10965798 [TBL] [Abstract][Full Text] [Related]
7. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347 [TBL] [Abstract][Full Text] [Related]
8. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Pletnikova O; West N; Lee MK; Rudow GL; Skolasky RL; Dawson TM; Marsh L; Troncoso JC Neurobiol Aging; 2005; 26(8):1183-92. PubMed ID: 15917102 [TBL] [Abstract][Full Text] [Related]
9. Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Takeda A; Hashimoto M; Mallory M; Sundsumo M; Hansen L; Sisk A; Masliah E Lab Invest; 1998 Sep; 78(9):1169-77. PubMed ID: 9759660 [TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein-positive structures in association with diffuse neurofibrillary tangles with calcification. Hishikawa N; Hashizume Y; Ujihira N; Okada Y; Yoshida M; Sobue G Neuropathol Appl Neurobiol; 2003 Jun; 29(3):280-7. PubMed ID: 12787325 [TBL] [Abstract][Full Text] [Related]
11. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein]. Iwatsubo T Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099 [TBL] [Abstract][Full Text] [Related]
12. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Galvin JE; Uryu K; Lee VM; Trojanowski JQ Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341 [TBL] [Abstract][Full Text] [Related]
13. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Hashimoto M; Rockenstein E; Crews L; Masliah E Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050 [TBL] [Abstract][Full Text] [Related]
14. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders. Krüger R; Müller T; Riess O J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401 [TBL] [Abstract][Full Text] [Related]
15. [The mechanism of Lewy body formation in Parkinson's disease]. Wakabayashi K; Takahashi H Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441 [TBL] [Abstract][Full Text] [Related]
16. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892 [TBL] [Abstract][Full Text] [Related]
17. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Norris EH; Giasson BI Antioxid Redox Signal; 2005; 7(5-6):672-84. PubMed ID: 15890012 [TBL] [Abstract][Full Text] [Related]
18. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Wakabayashi K; Tanji K; Mori F; Takahashi H Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486 [TBL] [Abstract][Full Text] [Related]
19. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies. Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732 [TBL] [Abstract][Full Text] [Related]